drugset / Trial / NCT05306041
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluation of the potential incremental efficacy and safety of inavolisib in the neoadjuvant endocrine treatment of early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer.
Timeline
- Start
- 2023-01-02
- Primary completion
- 2026-10
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inavolisib | Small molecule | 9 mg | — |
| Background | Phesgo | Unknown | — | Subcutaneous |
| Background | Tamoxifen | Small molecule | 20 mg | — |